Payment overview · 2025
General Payments
$7,607.00
404 reported records · 43 companies
Healthcare provider profile · identity verified
Sadiq Lafta Altamimi, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Clinical Neurophysiology · POMONA, CA · NPI 1639381619
Verified facts
What the public records show
CMS Open Payments records show Sadiq Lafta Altamimi, MD received $7,607.00 in general payments during 2025 across 404 reported records.
UCB, Inc. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Gamunex-C, Nuplazid, Panzyga, Qulipta, Rexulti, Tysabri, Ultomiris.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Qulipta by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuplazid by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART as an associated drug or biological on 6851 records involving 2825 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vyvgart by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Soliris by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ULTOMIRIS as an associated drug or biological on 24281 records involving 10608 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ultomiris by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tysabri by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gamunex-C by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Octapharma USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 1567 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Panzyga by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Panzyga by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Gammagard Liquid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $1,059.62 | 13.9% | 58 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $892.73 | 11.7% | 68 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $599.48 | 7.9% | 30 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $404.04 | 5.3% | 27 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $389.09 | 5.1% | 11 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $373.56 | 4.9% | 26 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $323.57 | 4.2% | 23 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $323.53 | 4.2% | 21 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $316.85 | 4.2% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $276.16 | 3.6% | 10 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $249.04 | 3.3% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $223.87 | 2.9% | 11 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $216.80 | 2.9% | 9 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $181.72 | 2.4% | 7 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $166.37 | 2.2% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $163.56 | 2.1% | 6 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $161.00 | 2.1% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $114.82 | 1.5% | 5 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$97.12 | 1.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.69 | 1.3% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $85.71 | 1.1% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $83.66 | 1.1% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $83.57 | 1.1% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $69.37 | 0.9% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $57.71 | 0.8% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $51.32 | 0.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.92 | 0.7% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $47.06 | 0.6% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $46.99 | 0.6% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $42.65 | 0.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $37.76 | 0.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $33.17 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.39 | 0.4% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.92 | 0.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $29.38 | 0.4% | 1 | 2025 |
| NEUROPACE, INC. | Unresolved — no canonical attribution shown | $29.20 | 0.4% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $28.98 | 0.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.26 | 0.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.02 | 0.3% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.08 | 0.3% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $23.08 | 0.3% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.61 | 0.2% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.57 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,560.01 | 403 |
| Education | $46.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $837.42 | 49 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $827.90 | 63 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $442.63 | 27 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $441.97 | 40 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $436.17 | 19 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $404.04 | 27 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $373.56 | 26 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $323.57 | 23 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $313.50 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $298.62 | 20 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $298.62 | 20 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $276.16 | 10 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $269.12 | 10 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $268.78 | 11 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $249.04 | 11 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $223.87 | 11 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $166.37 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $162.89 | 10 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $161.00 | 8 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $149.49 | 7 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $95.69 | 4 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $86.85 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $85.71 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $83.10 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $72.71 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $67.56 | 3 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $57.27 | 2 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $54.66 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $51.32 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $49.92 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $47.06 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $46.99 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $42.63 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $40.94 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $37.76 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $33.17 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $29.38 | 1 | 2025 |
Source payment records
|
|||||
| RNS Neurostimulator Kit Normalized: rns neurostimulator kit |
Device | NEUROPACE, INC. | $29.20 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $28.26 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| AGAMREE Normalized: agamree |
Drug | CATALYST PHARMACEUTICALS, INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $13.37 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 124 | exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ULTOMIRIS ultomiris |
2025 | Ultomiris | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
124 | 45 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART open payments reported associated product |
CMS Open Payments — General Payments 6851 supporting records · 2825 recipient NPIs · example record 1240416066 |
Vyvgart · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ULTOMIRIS open payments reported associated product |
CMS Open Payments — General Payments 24281 supporting records · 10608 recipient NPIs · example record 1202912926 |
Ultomiris · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Octapharma USA, Inc. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 1567 supporting records · 974 recipient NPIs · example record 1245074635 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
188 | 26 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 915 | 231 |
| Donepezil Hcl | Donepezil Hcl | 399 | 122 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 388 | 106 |
| Gabapentin | Gabapentin | 383 | 123 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 371 | 55 |
| Primidone | Primidone | 289 | 72 |
| Levetiracetam | Levetiracetam | 246 | 64 |
| Rivastigmine | Rivastigmine Tartrate | 237 | 50 |
| Lamotrigine | Lamotrigine | 193 | 43 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 188 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 176 | 41 |
| Clonazepam | Clonazepam | 157 | 40 |
| Baclofen | Baclofen | 156 | 47 |
| Oxcarbazepine | Oxcarbazepine | 155 | 26 |
| Botox | Onabotulinumtoxina | 124 | 45 |
| Pregabalin | Pregabalin | 123 | 42 |
| Sodium Chloride | 0.9 % Sodium Chloride | 99 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 26 |
| Diazepam | Diazepam | 89 | 26 |
| Amantadine | Amantadine Hcl | 86 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 23 |
| Topiramate | Topiramate | 77 | 15 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 73 | suppressed |
| Lacosamide | Lacosamide | 72 | 16 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 71 | 18 |
| Trazodone Hcl | Trazodone Hcl | 71 | 17 |
| Prednisone | Prednisone | 60 | 14 |
| Memantine Hcl Er | Memantine Hcl | 57 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 57 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | 17 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 56 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | suppressed |
| Methocarbamol | Methocarbamol | 54 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 51 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 47 | 21 |
| Propranolol Hcl | Propranolol Hcl | 45 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 44 | 14 |
| Ultomiris | Ravulizumab-Cwvz | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | 18 |
| Carbamazepine Er | Carbamazepine | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | 14 |
| Entacapone | Entacapone | 38 | 11 |
| Aimovig Autoinjector | Erenumab-Aooe | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 14 |
| Emgality Pen | Galcanezumab-Gnlm | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Zonisamide | Zonisamide | 33 | suppressed |
| Dalfampridine Er | Dalfampridine | 31 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 29 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 28 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 26 | 14 |
| Neupro | Rotigotine | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 25 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Vyvgart | Efgartigimod Alfa-Fcab | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 21 | suppressed |
| Qulipta | Atogepant | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Rytary | Carbidopa/Levodopa | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Austedo | Deutetrabenazine | 18 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 18 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 18 | suppressed |
| Soliris | Eculizumab | 18 | suppressed |
| Trokendi Xr | Topiramate | 18 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 17 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Horizant | Gabapentin Enacarbil | 12 | suppressed |
| Tysabri | Natalizumab | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fingolimod | Fingolimod Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,607.00 · 404 records | UCB, Inc. | AGAMREE, AMVUTTRA, AMYVID, AUSTEDO XR, BOTOX, CREXONT, FABRAZYME, FIRDAPSE, Fintepla, Gamunex-C, General - Pain Management, Gocovri, HYQVIA, INBRIJA, INFINITY, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, QUTENZA, REXULTI, RNS Neurostimulator Kit, Radicava, Rystiggo, SKYCLARYS, Symbravo, TANLOR, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYEPTI, VYVGART HYTRULO, WAINUA, XYWAV, Xeomin, ZAVZPRET, ZEMBRACE SYMTOUCH, ZEPOSIA | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error